Related Experiment Videos
Low-dosage mitomycin C as an adjunct to trabeculectomy. A prospective controlled study
E Martini1, G L Laffi, C Sprovieri
1Department of Physiopathologic Optics, University of Bologna, Italy.
European Journal of Ophthalmology
|January 1, 1997
Summary
Intraoperative low-dose Mitomycin C significantly improves success rates in glaucoma surgery compared to standard trabeculectomy. This adjunct therapy reduces intraocular pressure and the need for additional glaucoma medications.
Area of Science:
- Ophthalmology
- Surgical Innovation
Background:
- Glaucoma surgery aims to reduce intraocular pressure (IOP) to prevent optic nerve damage.
- Trabeculectomy is a common filtering procedure, but success rates can vary.
- Mitomycin C is an antifibrotic agent used to enhance surgical outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of intraoperative low-dose Mitomycin C (MMC) in trabeculectomy for uncontrolled glaucoma.
- To compare the success rates and adverse effects of MMC-augmented trabeculectomy versus standard trabeculectomy.
Main Methods:
- A randomized controlled trial involving 48 patients with uncontrolled glaucoma.
- Sixty eyes were divided into two groups: standard trabeculectomy and trabeculectomy with intraoperative 0.1 mg/ml MMC.
- Follow-up duration was at least one year.
Main Results:
- The MMC group achieved a success rate of 96.6% versus 73.3% in the control group (IOP < 18 mmHg).
- Mean IOP at one year was significantly lower in the MMC group (11.1 +/- 3.1 mmHg) compared to controls (16.4 +/- 6.1 mmHg; p < 0.0001).
- Fewer patients in the MMC group required antiglaucomatous drugs (6.6%) compared to the control group (20%).
Conclusions:
- Low-dose intraoperative Mitomycin C is an effective adjunct to trabeculectomy, improving surgical success.
- Adverse effects, primarily hypotony, can be mitigated by using a two-layer suture technique.
- MMC offers a valuable option for enhancing standard primary trabeculectomy outcomes.